礼来与生物技术公司Repertoire达成合作协议 共同开发自体免疫疾病疗法

格隆汇
Jan 29

生物技术公司Repertoire宣布与礼来公司达成战略合作,将共同开发针对多种自体免疫疾病的耐受疗法。该合作旨在开发能够恢复免疫稳态的治疗方案,使患者在无需承受当前常见疗法导致的全身性免疫抑制的情况下,实现疾病的持久缓解。根据协议,Repertoire将获得8500万美元首付款,并在达成特定研发与商业里程碑后获得最高18.4亿美元的额外款项,同时还可基于净销售额获得分级特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10